Related references
Note: Only part of the references are listed.ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity
Hideki Kimura et al.
LUNG CANCER (2012)
Identification of cyclophilin-40-interacting proteins reveals potential cellular function of cyclophilin-40
Miki Susanto Park et al.
ANALYTICAL BIOCHEMISTRY (2011)
The role of FKBP5 in cancer aetiology and chemoresistance
L. Li et al.
BRITISH JOURNAL OF CANCER (2011)
Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer
Takashi Kijima et al.
CANCER SCIENCE (2011)
Crizotinib in Anaplastic Large-Cell Lymphoma
Carlo Gambacorti-Passerini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models
E. Normant et al.
ONCOGENE (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
Takaaki Sasaki et al.
CANCER RESEARCH (2010)
Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
Zhao Chen et al.
CANCER RESEARCH (2010)
Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells
S. Romano et al.
CELL DEATH AND DIFFERENTIATION (2010)
Susceptibility to Diet-Induced Hepatic Steatosis and Glucocorticoid Resistance in FK506-Binding Protein 52-Deficient Mice
Manya Warrier et al.
ENDOCRINOLOGY (2010)
Functional Characterization of the Kinase Activation Loop in Nucleophosmin (NPM)-Anaplastic Lymphoma Kinase (ALK) Using Tandem Affinity Purification and Liquid Chromatography-Mass Spectrometry
Peng Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
Mikko Taipale et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
James E. Butrynski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A
S. Periyasamy et al.
ONCOGENE (2010)
Targeting the dynamic HSP90 complex in cancer
Jane Trepel et al.
NATURE REVIEWS CANCER (2010)
Proteome-Wide Identification of Novel Binding Partners to the Oncogenic Fusion Gene Protein, NPM-ALK, using Tandem Affinity Purification and Mass Spectrometry
Fang Wu et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt
Huadong Pei et al.
CANCER CELL (2009)
Cyclophilin 40: An Hsp90-cochaperone associated with apo-steroid receptors
Thomas Ratajczak et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors
J. R. Smith et al.
ONCOGENE (2009)
Cyclophilin 40 is required for microRNA activity in Arabidopsis
Michael R. Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
Ultan McDermott et al.
CANCER RESEARCH (2008)
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer
Young Lim Choi et al.
CANCER RESEARCH (2008)
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi P. Koivunen et al.
CLINICAL CANCER RESEARCH (2008)
A mouse model for EML4-ALK-positive lung cancer
Manabu Soda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase
Carmen J. Tartari et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
James G. Christensen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context
Maria A. Theodoraki et al.
EXPERIMENTAL CELL RESEARCH (2007)
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling
Philipp B. Staber et al.
BLOOD (2007)
Pathobiology of ALK+ anaplastic large-cell lymphoma
Hesham M. Amin et al.
BLOOD (2007)
Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells
Jonathan A. Schumacher et al.
PROTEOMICS (2007)
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression
Georglos V. Georgakis et al.
EXPERIMENTAL HEMATOLOGY (2006)
The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner
Faye Yuan-Yi Hsu et al.
CANCER RESEARCH (2006)
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells
WH Wan et al.
BLOOD (2006)
The Epstein-Barr virus protein, latent membrane protein 2A, co-opts tyrosine kinases used by the T cell receptor
RJ Ingham et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
JunB expression is a common feature of CD30+lymphomas and lymphomatoid papulosis
GZ Rassidakis et al.
MODERN PATHOLOGY (2005)
Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506
TH Davies et al.
BIOCHEMISTRY (2005)
FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells
GM Wochnik et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
FKBP52
TH Davies et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: Role of the co-chaperone carboxyl heat shock protein 70-interacting protein
P Bonvini et al.
CANCER RESEARCH (2004)
High affinity binding of Hsp90 is triggered by multiple discrete segments of its kinase clients
BT Scroggins et al.
BIOCHEMISTRY (2003)
The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo
DL Riggs et al.
EMBO JOURNAL (2003)
JunB inhibits proliferation and transformation in B-lymphoid cells
AP Szremska et al.
BLOOD (2003)
Immunophilin chaperones in steroid receptor signalling
T Ratajczak et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2003)
Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB
S Mathas et al.
EMBO JOURNAL (2002)
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
A Zamo et al.
ONCOGENE (2002)
Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma
Q Zhang et al.
JOURNAL OF IMMUNOLOGY (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding
WB Denny et al.
ENDOCRINOLOGY (2000)
TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
B Lawrence et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
